PMDA drug package insert
カドサイラ点滴静注用100mg
PMDA Prescription drug · 中外製薬株式会社 · package insert Nov 29, 2024
Key facts
| Brand names | カドサイラ点滴静注用100mg, カドサイラ点滴静注用160mg |
|---|---|
| Nonproprietary names | トラスツズマブ エムタンシン（遺伝子組換え） |
| Companies | 製造販売元／中外製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗HER2 抗体チューブリン重合阻害剤複合体 HER2：Human Epidermal Growth Factor Receptor Type 2（ヒト上皮増殖因子受容体2型、別称：c-erbB-2） |
| Therapeutic category codes | 874291 |
| YJ codes | 4291426D1026, 4291426D2022 |
| Approval numbers | 22500AMX01816, 22500AMX01817 |
| Package insert edition | 第7版 |
| Package insert date | Nov 29, 2024 |
| PMDA document key | 450045_4291426D1026_1 |
| PMDA company code | 450045 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: